Claims
- 1. A method for the treatment and/or prevention of diseases induced by abnormal enhancing of degradation of proteins by the action of elastase in mammals subject to or suffering therefrom, which comprises administering an effective amount of derivatives of p-guanidinobenzoic acid of the general formula: ##STR38## where Y represents an oxygen atom R represents a halogen atom, and R.sup.2 represents
- (i) a hydrogen atom,
- (ii) an alkyl group of one to four carbon atoms,
- (iii) an alkoxy group of one to four carbon atoms,
- (iv) an alkoxymethyl group of two to five carbon atoms,
- (v) a group represented by the formula: COOR.sup.3, wherein R.sup.3 represents a hydrogen atom or an alkyl group of one to four carbon atoms,
- (vi) a group represented by the formula: CH.sub.2 COOR.sup.3, wherein R.sup.3 has the same meaning as described hereinbefore,
- (vii) a group represented by the formula: CH.dbd.CH--COOR.sup.3, wherein R.sup.3 has the same meaning as described hereinbefore,
- (viii) a halogen atom,
- (ix) a trifluoromethyl group
- (x) a group represented by the formula: COR.sup.4, wherein R.sup.4 represents an alkyl group of one to four carbon atoms, a phenyl group, a guanidinophenyl group, a cyclopentylmethyl group or a cyclohexylmethyl group,
- (xi) a group represented by the formula: OCOR.sup.4, wherein R.sup.4 has the same meaning as described hereinbefore,
- (xii) a group represented by the formula: CH.sub.2 OCOR.sup.4, wherein R.sup.4 has the same meaning as described hereinbefore,
- (xiii) a group represented by the formula: SO.sub.2 R.sup.4, wherein R.sup.4 has the same meaning as described hereinbefore,
- (xiv) a group represented by the formula: OSO.sub.2 R.sup.4, wherein R.sup.4 has the same meaning as described hereinbefore,
- (xv) a group represented by the formula: CONR.sup.5 R.sup.6, wherein R.sup.5 and R.sup.6 represent a hydrogen atom, an alkyl group of from one to four carbon atoms, a phenyl group, a benzyl group, a pyridyl group independently, or R.sup.5, R.sup.6 and a nitrogen atom, to which R.sup.5 and R.sup.6 are linked, together represent a pyrrolidinyl group, a piperidino group or a morpholino group,
- (xvi) a group represented by the formula: OCONR.sup.5 R.sup.6, wherein R.sup.5 and R.sup.6 have the same meaning as described hereinbefore,
- (xvii) a group represented by the formula: SO.sub.2 NR.sup.5 R.sup.6, wherein R.sup.5 and R.sup.6 have the same meaning as described hereinbefore;
- (xviii) a group represented by the formula: ##STR39## wherein R.sup.5 and R.sup.6 have the same meaning as described hereinbefore,
- (xix) a group represented by the formula: NHSO.sub.2 R.sup.7, wherein R.sup.7 represents an alkyl group or from one to four carbon atoms or a phenyl group,
- (xx) a nitro group,
- (xxi) a hydroxy group,
- (xxii) a hydroxymethyl group,
- (xxiii) a guanidino group,
- (xxiv) a benzyloxy group,
- (xxv) a guanidinophenylthiomethyl group,
- (xxvi) a morpholinosulfonylphenoxymethyl group,
- (xxvii) a pyridyloxymethyl group, or
- (xxviii) a (1,1-dioxothiazol-3-yl)carbonyl group,
- and n" represents an integer of one to four, and (1) when n" represents two or more, each of R.sup.2 may be the same group or a different group, and (2) when R represents a 3-chloro atom, R.sup.2 does not represent 5-OSO.sub.2 R.sup.4, wherein R.sup.4 has the same meaning as described hereinbefore, or a non-toxic acid addition salt thereof.
- 2. A method according to claim 1 in which the active ingredient is p-guanidinobenzoic acid 3-chloro-5-hydroxyphenyl ester.
Priority Claims (3)
Number |
Date |
Country |
Kind |
60-252066 |
Nov 1985 |
JPX |
|
60-250067 |
Nov 1985 |
JPX |
|
61-192117 |
Aug 1986 |
JPX |
|
Parent Case Info
This is a division of application Ser. No. 06/929,317, filed 11/12/86 now U.S. Pat. No. 4,843,094.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4283418 |
Fuji et al. |
Aug 1981 |
|
4843094 |
Imaki et al. |
Jun 1989 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
929317 |
Nov 1986 |
|